Dear Friends,
A new year in the offing (5771) and we still find ourselves facing economic and political uncertainty. Gilad Shalit is in his fourth year of captivity at the hands of the Hamas.
Here at the Tel Aviv Sourasky Medical Center, we have set our goals for the coming year: "We continue to strive for excellence in every area; superior clinical care, superior service and superior logistical capabilities in particular." With those words, Dr. Ronni Gamzu, Director of the General Hospital lately (and today is serving as the Director of the Ministry of Health), opened the most recent 2009 Summary Conference. The conference also set out the TASMC's goals for the coming year.
In 2009, the hospital increased its activities in the area of ambulatory care, in the number of surgeries performed, and in the number of births.
Recently, the hospital added a new MRI machine in the new MRI unit for diagnosis of women with breast disease. The MRI was purchased with the help of *(1) the Bonita Trust.
Funds for the construction of a hybrid operating room - surgery with angiography capabilities - have been donated by the Wolfson Foundation.
We expect the Sammy Ofer Heart Tower to be completed in October 2010, with a move-in date projected for the beginning of 2011. "With the completion of the Ofer Tower, we will have realized a dream that began 15 years ag To end all hospitalizations in the old building, and to transfer all of the medical units in the old building to new, updated quarters in the new building," said Prof. Gabi Barbash, the Director General at the TASMC's annual conference.
The pediatric clinics have moved into their new home next to the rehabilitation building, and this completed stage I of the construction of the new pavilion. For this we wish again to express our heartfelt thanks to our generous benefactors who helped us bring this project to fruition: The Dwek Family, the Abramson Family Foundation and I.D.B. Group. Now we are toward building stage II which includes an underground, sheltered floor spread over 1,200 sqm. There's a connecting tunnel to the Dana-Dwek Children Hospital. Additionally, a ground floor that is spread over 1,000 sqm, and a porch playground area spread over 940 sqm. To complete stage II we need to recruit about 6 million dollars.
We are in the advanced stages of the construction of a new ophthalmology clinic, through the help of a beloved, longtime friend and benefactor of ours, Mrs. Rose Landschaft.
In our previous newsletter, we announced the launching of a new project named: *(2)"Adopt a Researcher". It's a project we decided to take upon ourselves to advance and support along with the TASMC's Research and Development Department, headed by Dr. Michal Roll. We are proud to announce that so far we have 5 "adopted researchers" (out of the 15 who need to be "adopted"). We will update you on the areas of research that our benefactors have chosen to support.
There are many challenges ahead, and we hope this New Year will bring good news for all of us.
Wishing you and your families a wonderful year.
Sincerely yours,
Ronit Blum
Director, Friends of the TASMC
*(1) THE BONITA TRUST
The Bonita Trust, headed by Mr. Moe Cohen, was founded in 2004 in Gibraltar, as a philanthropic organization that principally supports medical, educational, cultural and sports projects and organizations. The Bonita Trust donated $250,000 to the TASMC for the purchase of urgently needed medical equipment.
The Bonita Trust has recently donated 1 (One) million dollars for the purchase of a new MRI scanner that will be dedicated to the surge of referrals for breast examinations. "Bonita Trust MRI Suite" will help cater for the major changes that have recently taken place in breast cancer screening protocols requiring the performance of repeated MRI studies.
Speaking on behalf of Bonita's International Advisory Board, Ruth Parasol DeLeon noted " It is a pleasure to continue our existing relationship with the Tel Aviv Sourasky Medical Center. Helping the early detection of breast cancer will save many
lives. This is another clear demonstration of Bonita's ongoing commitment to some of the global health challenges we are facing".
*(2) What's new with "Adopt-a-Researcher" project program?
To date, 5 researchers have been "adopted" as part of the Adopt-a-Researcher program of the TASMC's Friends Association. The five studies will each receive financial help from their donors for a period of three years. The 4 topics of research that have been chosen are:
Mechanism of Viral Hepatitis Infection
Colon cancer- genetic and environmental factors
Infections in immunocompromised patients
Pathophysiology of placenta development
We hope that we will succeed in reaching our goal of helping another 10 researchers develop their studies that ultimately will help us all.
HERMETIC TRUST SERVICES
The Hermetic Trust Services recently transferred a donation of $130,000 on behalf of an anonymous donor to acquire 2 continuous EEG monitoring system for the Pediatric Neurology Epilepsy Unit and for the Neurology Epilepsy Unit. Another $100,000 donation was recently approved by the Hermetic Trust Services for the purposes of acquiring two video bronchoscopy machines for use in the Pediatric E.N.T. Department and the Pediatric Intensive Care Unit.
Hermetic was founded in 1975 and it supports both private and institutional clients.
An article in Israel's "The Marker" business journal on the 13th of May, 2010 noted that Israel's Ministry of Health has ranked the TASMC in first place for obtaining grant funding for its clinical trials.
Some of the major points of the article:
* The Ministry of Health's annual report has ranked our medical center as number
one in grant funding for its clinical research studies, in collaboration
or sponsored by bio-pharmaclinical companies (both Israeli and International).
* Our grant fund ing income is by far higher than the next hospital- Rabin Medical
Center (Belinson) (by more than 20%).
* In addition, the report states that the TASMC has signed more contracts than any
other hospital in Israel and has several medical opinion leaders who attract the big
pharmaceutical companies.
* The TASMC has been growing steadily in research activities and their funding in
the last decade, rising from the status of a peripheral medical research center to a
prominent leader in clinical as well as translational research.
Expected Income From Clinical Research for Year 2009
[Official Data from Ministry of Health]
|
10 Million Shekels in Grant for Parkinson's Disease Research Donated to the TASMC
PARKINSON'S: A FAMILY STORY
The TASMC has received 10 million shekels in grant funding this year towards a major study it is conducting on Parkinson's Disease. The grants come from competing Israeli and International foundations to help fund the Parkinson's study at the TASMC, led by Prof. Nir Giladi, the head of the Neurology Department at TASMC and Prof. Avi Orr-Ortreger, the head of the Genetic Institute at TASMC . The study is being conducted by a team made up of the researchers staff from the Genetic Institute, the Movement Disorders Unit, the Functional Imaging Unit and the Institute for Nuclear Medicine.
Until recently, Parkinson's Disease wasn't considered a genetic problem. Our groundbreaking study has confirmed the existence of several genetic mutations that are the cause of Parkinson's. The study has also discovered clinical indicators for healthy carriers of those genetic mutations. The grant funds were donated for the purpose of expanding the study to explore new solutions for the prevention and cure of the disease.
"In 2005, the TASMC singled out our genetic study of Parkinson's Disease for excellence," said the head of the study, Prof. Giladi. "The hospital budgeted $300,000 for the study, to be spread out evenly over three years. This internal grant enabled us to take the first steps on this project, and helped us realize the enormous importance and implications of our findings."
"The results of the study were published in the New England Journal of Medicine at the beginning of 2006. This was just a few months after we had begun gathering genetic information about Parkinson's patients in Israel. That information we had gathered indicated that some of the Parkinson's patients, who were of Ashkenazic Jewish descent, carried a specific mutation of the LRRK2 gene which contributed to the development of their disease. This early indication of a pattern set off alarm bells for us, and served as a catalyst for our research." according to Prof. Giladi.
Who will fall sick with the disease, and who will not? That is the most important question, and it's answer could bring about the development of a preventative treatment for Parkinson's Disease. Prof. Giladi and Prof. Orr-Ortreger emphasize that based upon what is known today, less than two thirds of those carriers of the genetic mutation will contract the disease. Some 25% of them will live a full, disease-free life. The two physician researchers note that this study being conducted in Israel,
along with a study being conducted in New York represent a real source of hope for those who carry the genetic mutation for Parkinson's Disease. Based on these studies, and on those hold by other group who are studying the genetic basis for Parkinson's, it will be possible in the not-so-far future to identify the disease in its early stages (that period where the disease is settling upon the brain, but the person is still leading a full life, unaware of the disease's existence in their brain). Effective early treatment could possibly delay the development of Parkinson's or slow the rate of its degenerative effects or even reduce the severity of the disease.
Prof. Giladi lays out the work ahead for the researchers as a three-pronged goal:
A genetic project: To characterize the genetic structure that is responsible for the development of Parkinson's and discover how to prevent its development.
A clinical project: To characterize which patients carry the genetic mutation as well as family members with the potential for this mutation that have not yet been diagnosed with Parkinson's
An imaging project : To use advanced imaging technology to map out the parts of the brain that are affected early on, to identify early impairment of movement which can be sensitive diagnostics indicating the pre-clinical existence of the disease.
A special grant to the Gait Laboratory of the Movement Disorders Unit
The gait laboratory of the Movement disorders Unit of the Neurology Department, headed by Prof. Jeff Hausdorf, a distinguished researcher in gait disorders in the elderly, has also received several generous grants recently: An RO1 grant from the U.S. N.I.H. - U.S. National Institutes Health *(1), (and it is not the first time Prof. Hausdarf receives such a grant from the NIH). EU - European Union*(2) grant in the FP7 program, from the Michael J. Fox Foundation*(3) and from the ISF (Israel Science Foundation) and more.
*(1) The National Institutes of Health (NIH) are part of the US department of Health services . NIH's mission is to seek fundamental knowledge about the nature and behavior of living systems and the application of that knowledge to enhance health, lengthen life, and reduce the burdens of illness and disability The NIH invests over $31.2* billion annually in medical research for the American people. More than 80% of the NIH's funding is awarded through almost 50,000 competitive grants to more than 325,000 researchers at over 3,000 universities, medical schools, and other research institutions in every state and around the world. Naturally, it is very difficult for overseas institutes and researchers to receive funding from the NIH and in particular to be the leaders for research projects funded by them, very few Israeli researchers have such grants.
*(2) The European Union: RTD Programs Foundation: Israel is a member of the RTD Foundation, the research arm of the European Union's institutions, since 2004. This has enabled the TASMC to take part in cooperative research between several countries. It has also enabled us to obtain funding for our research from the European Union.
*(3) The Michael J. Fox Foundation: Michael J. Fox is a famous television and movie actor who was diagnosed with Parkinson's disease in 1991. In 1998, he announced his condition to the public. In the year 2000, symptoms of the disease became more severe and so Mr. Fox retired from the entertainment business to devote his time to family and to fighting this disease. He also established a foundation devoted to finding the cure for Parkinson's Disease. The foundation supports research in the field all over the world in order to help people understand the disease better. They also help develop treatments and medicines for the disease, as well as search for a way to improve the lives of those who suffer from this debilitating disease.
New services:
PLAC Test: An event you CAN predict!
A simple blood test can prevent a stroke or a heart attack
Every year there are 15,000 new patients of stroke in Israel. It attacks about a 1/4 to 1/3 of the population below 60. It's the leading cause of handicaps for adults and the second leading cause of death after cardiac disease.
90% of all strokes are caused by a clot of the blood vessels in the brain cells. This thrombosis is caused by intra-cranial blood vessel clotting, or blood clots that were swept in to the brain's vascular network (embolism). In the other 10%, a stroke is cause by intra-cranial bleeding. The clot that blocks the blood causes ischemia to the brain, which in turn causes the brain cells to die and cerebral infarction-- much like myocardial infarction.
Sometimes the stroke gives early signs that are short and transitory such as: - weakness and sudden paralysis of parts of the body (the most common sign), the sudden inability to speak or understand speech, dizziness or impaired coordination or vision and sudden tingling or paresthesia of numbness of parts of the body.
There are also some risk factors to strike such as: High blood pressure, diabetes, metabolic syndromes, smoking, elevated blood cholesterol or sclerosis of the cardiac vascular system and/or other major organs and life style as lack of exercise, alcohol abuse or obesity.
Recently, the TASMC introduced a new blood test that is called a PLAC test and it is carried out by a simple blood sampling. This blood test can predict more accurately the chances of a stroke occurring in a patient that does not fit in any of the traditional high risk groups. If a patient gets a high factor on the PLAC test, this denotes increased risk of embolism and therefore increased risk of cardiac arrest or stroke so he can be given an individualized treatment according his results.
Recently, a new facility for early skin cancer detection was established in the department of dermatology at the TASMC.
Among the most devastating skin cancers, melanoma ranks first by far. The prevalence of melanoma in Israel is the second highest rate worldwide. Early detection is crucial in the case of melanoma as the possibilities of treatment are rather limited for advanced disease. In contrast, early diagnosis promises very high survival rate.
Recently a new facility for early skin cancer detection was established in the department of dermatology at the Tel Aviv Medical Center, managed by Dr. Helena Martinez. Dr. Martinez is a senior physician at the Department of Dermatology at the TASMC and she directs the clinic for early detection of skin cancer. Dr. Martinez has been part of the Department for the last 10 years, and has sub-specialized in the field of Dermoscopy. Dermoscopy refers to a relatively new technology which has shown to significantly improve the diagnostic accuracy of the early detection of skin cancer.
In contrast with a regular mole examination, patients undergo a thorough physical examination which is always complemented with dermoscopic assessment. In addition, full body photography enables Dr. Martinez to provide long term follow up based on a comparison of body photographs regularly taken over the years. The fact that the patients are given a CD including all clinical photos, enables them to perform frequent self-examination.
A meticulous follow up is offered to the patient after primary evaluation, including dermoscopic monitoring of the troublesome lesions. The follow up intervals depend upon each patient's risk level for developing melanoma.
Altogether, this new state-of-the-art facility provides our patients with the most advanced means for prevention of the most common form of cancer in humans, skin cancer.
Clinic for the treatment of chronic ulcers and hard-to-heal wounds
A cooperative effort between the Dermatology and Plastic Surgery Units helped form a new clinic which offers assessment, diagnosis and treatment of chronic ulcers and open wounds.
A specialized unit that treats chronic ulcers and hard-to-heal wounds has opened in the TASMC. The clinic is the result of a cooperative effort between the Dermatology and Plastic Surgery departments of the TASMC. Chronic ulcers are deep tissue sores that are still open wounds after six weeks or more, despite medical treatment. These types of chronic wounds of the lower limbs are estimated to afflict about 3-5% of the population above the age of 65. The frequency of these types of wounds is on the increase as the population ages and the risks of thrombosis from diabetes, smoking and obesity rise.
Because of the complicated nature of the epidermal disease, and because of the manifold factors that cause these wounds, the rates of successful healing is particularly low, and the rate of recurrence is high amongst most patients with chronic ulcers that are treated in the community.
Our innovative and multidisciplinary clinic at the TASMC specializes in the care of ulcers and open sores. The clinic answers an urgent need for those patients with chronic ulceration, such as those commonly found to afflict patients suffering from diabetes or other cellular diseases, as well as for patients with hereditary or contagious skin diseases that tend to suffer from ulcerated skin or hard-to-heal sores.
The clinic's services include a thorough assessment and diagnosis of the basic illness and cause of the ulcer. This will involve caregivers from several medical disciplines who make up the clinic's team, as needed. The treatment may also include surgical excision or an epidermal biopsy, as well as wound dressing and care. The careful, individualized treatment is meticulously carried out based upon the etiology of the disease and the nature of the ulcers. Wound dressing is performed by a highly skilled staff of nurses who are specifically trained in this area.
Clinical Trial:
A New Blood Test for CD24 Protein Can Detect Colorectal Adenomas and Adenocarcinomas
A new test for CD24 protein as a potential biomarker for the early detection of colorectal cancer (CRC) was recently developed at the TASMC by the Integrated Cancer Prevention Center team. The center is headed by Prof. Nadir Arber. The test involves the detection of CD24, a cell surface glycoprotein and P-selectin ligand, in peripheral blood leukocytes. This is the first blood test that can detect not only cancer but also adenomas, the pre-malignant lesion.
Colorectal cancer (CRC) is a major health concern worldwide. It is estimated that in 2010, there are going to be more than 1,000,000 new cases; half a million are going to die from the disease. CRC is a chronic disease that spans 2-3 decades from normal mucosa through adenoma to carcinoma. At the same time the disease is preventable in a significant number of cases. A number of screening modalities are recommended, each with related advantages and disadvantages that impact patient acceptance and compliance. Screening colonoscopy can prevent CRC in up to 90% of the cases. However, the acceptance of this screening modality is still quite low. A simple, noninvasive blood test that can detect CRC will have a significant impact on the eradication of CRC, as the public has no fear of blood tests. If a test is positive, the patient understands that they must undergo colonoscopy.
The results were recently presented at the 2010 ASCO (American Society of Clinical Oncology) Gastrointestinal Cancers Symposium. The work was chosen as one of only four presentations for the symposium's official Press Program, from among more than 500 abstracts submitted for presentation. It was also selected for presentation as a Poster of Distinction during the Digestive Disease Week, which was recently held in New Orleans.
Remarkable:
We are proud of :
The Pediatric Intensive Care Unit of the Dana-Dwek Children's Hospital at the TASMC was awarded the President's Prize for Excellence
On the 17th of February, 2010, the Pediatric Intensive Care Unit staff of the TASMC's Dana-Dwek Children's Hospital, led by Prof. Yaacov Sivan and Dr. Ephraim Sadeh, was awarded the President's Prize for excellence by Israel's President, Mr. Shimon Peres. The President received the team in the President's Residence in Jerusalem and awarded them the NIS 20,000 prize.
The Pediatric Intensive Care team comprises some 30 members; nurses, doctors and para-medical personnel, and is managed by Professor Yaacov Sivan and Dr. Ephraim Sadeh. The team is a highly skilled, dedicated, experienced and professional group that provides the highest standard of medical care around the clock. They work under conditions of high pressure, caring for children in difficult and complicated situations on the one hand. And they provide warmth and support and a shoulder to cry on for parents who are generally in the hospital under extremely difficult emotional circumstances, on the other hand. The TASMC's team works with total devotion, continually investing in professional advancement, such as learning new languages and obtaining new skills, in order to provide the best and most advanced medical care possible to both Israeli and foreign patients who enter its doors.
At the ceremony, Prof. Sivan said:
"There is no doubt about it: Professionalism is the key to our success. But in our field, professionalism is not the only ingredient to ensure success. What we need is something that goes well beyond professional knowledge or skill. It is not something that we can learn in medical or nursing school. It is not something we can easily teach, though it is easily discerned. It is something that our team members bring to this job, and is most clearly seen when they work together in tandem. It is the inner drive to do not just what is necessary, but rather to go beyond the call of duty, to utilize every bit of knowledge we possess, every ounce of experience we have garnered, to devote every thought and every sense of responsibility that we have-- all geared towards the goal of obtaining a better outcome for the patient."
"[What sets them apart] is the refusal to give up when they are tired or when things are difficult. It is their ability to function with calm efficiency and zero foul-ups-- all during the frantic moments when a child's blood pressure or pacemaker crashes, or while a monitor's screen is blinking and warning so loudly that your heart skips a beat-- drama on all sides."
"They are careful and precise in administering medication, in performing intubations, and in identifying early signs of danger, to react quickly and with the correct treatment, to fight maladies tirelessly and with determination, without compromise and without cutting corners. Without saying, ‘I'll get to it tomorrow', or ‘I'll do it later' or, ‘it'll be ok' or fudging off the patient. And to do all this, at every moment, on every day of the year, on holidays and weekends, every second of the day, round the clock and without a moment's respite from the tension and difficulties the team faces."
The TASMC's Pediatric Intensive Care Unit was also awarded the prize for excellence by the Tel Aviv-Jaffa municipality, on behalf of the Maariv newspaper.
Physicians in Buenos Aires gave up, but Professor Shlomi Constantini had other ideas: How 6-year old Argentinian Santiago Dachas' life was saved
The life of an Argentinian child was saved after he underwent a complex surgical procedure to remove a brain tumor at the TASMC. The operation on 6-year old Santiago Dachas was performed by our own Professor Shlomi Constantini.
Santiago suffered from a cancerous tumor in his brain, and a previous surgery to remove the tumor in Argentina had failed. His parents, Liliana and Milio refused to give up and began to search elsewhere for help. One of their neighbors inquired at the Israeli embassy in Argentina, which advised them to consult with the head of neurosurgery at the Dana Children's Hospital of the TASMC, Prof. Shlomi Constantini.
Prof. Constantini consulted with Santiago's Argentinian doctors, who described his dire medical situation as well as the range of treatments the boy had already undergone. Prof. Constantini decided the boy's chances of survival were good if he could get to Israel. Santiago's parents immediately began efforts to raise the funds needed to make the difficult and complicated flight to Israel as well as cover the costs of the operation. The Argentinian Jewish community mobilized to help the family, and even a local Argentinian radio station made an emotional plea to its listeners to open their hearts and wallets and help save Santiago's life.
All these efforts paid off. After an arduous 22 hour flight, Santiago arrived in Israel and immediately underwent a complex operation that lasted eight hours, to remove the tumor.
Santiago's recovery from surgery was excellent, and he consequently underwent supplementary oncological and radiation treatment. The supplemental treatment was carefully coordinated between the hemato-oncology pediatric unit and the radiation therapy unit, under the aegis of Dr. Daniel Augurk, who served both as a translator and a source of care and support to the family.
Upon the conclusion of his oncological treatment, Santiago and his family returned to Argentina, where the boy will continue to be under medical supervision.
"I have received the gift of my son's life," said a grateful and emotional Milio Dachas. Santiago's father offered his heartfelt thanks to the entire medical team for their enormous efforts on behalf of the family; and to the TASMC itself; the hospital helped the family even more by deciding to waive payment for the operation.
OUR CONTRIBUTION TO THE NATIONAL COMMUNITY
TASMC's Dr. Eckstein writes about her experience as part of a delegation to China to treat children with cleft palate
Dr. Margarite Ekstein from the Anaesthesia Department in the Tel Aviv Sourasky Medical Center joined a world-wide effort to treat children from third world countries who are born with anomalies. Between November 1st and 13th 2009, I, as 1 of 7 pediatric anesthesiologists, she was joined a medical mission sponsored by Alliance for Smiles. All together, they were 43 doctors, nurses, and other professionals who flew to Wenzhou, China. There they operated on and cured 148 children born with cleft palates and cleft lips. The children were between 3 months and 22 years old. They were born with faces that have a split in the upper lip up to their nose and sometimes even their upper palate This condition was so disfiguring that the children are often considered "messengers of the Devil." This condition affects 1.6/1000 births in the Far East, but many were so poor, and medical conditions so limited that curative surgery was simply not available to them.
The children that were taken care of and their families were literally reborn by this surgery. These children after the surgery can integrate into society, they can eat without food getting pushed out through the hole in the roof of their mouth into their nose; they can also learn to speak properly as this defect causes a serious speech problem.
Dr. Margarite Ekstein also had the special experience of teaching local Chinese anesthesiologists. This way she not only took care of 148 children, but also helped to train the professionals there to continue the job.
Dr. Margarite Ekstein said "There was a feeling of trust and mutual respect which was fostered by the AFS mediators even before we arrived. We helped build a local treatment center to continue and expand treatment of children who are born with facial defects. While in China, I felt I was a representative of Israel to the Chinese people (whose appreciation was boundless). I also represented Israel to the other volunteers, my teammates from the USA, UK, Australia, and Belgium, in this very important and uplifting mission".
Nominations:
Dr. Ronni Gamzu, Director of the General Hospital of the TASMC, has been appointed Director General of the Ministry of Health effective as of June, 2010.
Prof. Moshe Salai was nominated lately to the head of the Orthopedic Division in the Tel-Aviv Sourasky Medical Center.
He graduated the Sackler School of Medicine in Tel Aviv University. He served as a Director of the Orthopedic Oncology Service, the National Bone Bank and Department of Orthopedic Surgery B at The Chaim Sheba Medical Center.
He came to our medical center from Rabin Medical Center there he served in his last
job as the Director of the Orthopedic Division.
Prof. Rami Hershkoviz was nominated lately to the head of the Internal Medicine "TET" Department in TASMC..
Prof. Hershkoviz, a graduate of the Sackler faculty of Medicine in Tel Aviv University, began his professional career as resident in the same Internal Medicine "TET" Department headed by Prof. Yoram Levo, whom he is now replacing as department head.
Prof. Hershkoviz was the Head of the Internal Medicine Department at the Assaf Harofeh Hospital for the last ten years.
Concurrently with his clinical work during these years he served as visiting scientist at the Weizman Institute of Science, in the laboratory of the late Prof. Ofer Lider. Together with Prof. Lider, Prof. Hershkoviz was among the first scholars in this country to research and characterize the movement of lymphocytic cells to inflamed areas in a range of autoimmune and inflammatory diseases and established a basis for the development of various biological drugs to prevent inflammation.
Prof. Hershkoviz is active in the Sackler Faculty of Medicine in Tel Aviv University;
he serves as chairman of the Tuition Committee of the School for Continuing Studies; he is chairman of the committee that accompanies the Studies of Internal Medicine, and a member of the Appointments Committee of the Faculty.
Dr. Aharon Menachem, the deputy Manager of the Department of Orthopedic Surgery B was nominated to Deputy Manager in Department of Orthopedic Surgery A.
Dr. Ely Steinberg, who served at Department of Orthopedic Surgery B was nominated to Deputy Manager at the Department of Orthopedic Surgery B.
Dr. Ory Keynan, of the Department of Orthopedic Surgery B in TASMC was nominated to Head the Service for Degenerative and Age-Related Spinal Disorders.
In blessed memory of Lord Leonard Wolfson
Lord Leonard Wolfson passed away in May, 2010, at the age of 83. Lord Wolfson was one of Israel's greatest benefactors, donating generously in the fields of research, technology and medicine, to universities and hospitals alike. Lord Wolfson was praised as, among other things, a man who had the vision and the perseverance to see advancements and ideas translated in to actions.
Lord Wolfson was especially close with our own Prof. Gabi Barbash. The Wolfson Foundation, which Lord Wolfson headed for more than 40 years, helped the TASMC tremendously over the years. Offering funds for everything from a catheterization unit donated in 1997, to a gastroenterology institute, partnering to help buy three linear accelerators, our radiology institute and so on. Even now we are awaiting the approval of a grant to help in the construction of a hybrid operating room.
Lord Wolfson will be sorely missed. May his memory be a blessing. |
